A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer.

APX3330 - Apexian, Opus Genetics

http://www.ncbi.nlm.nih.gov/pubmed/40236444

Amber L Mosley; Bert O'Neil; Eyram Kpenu; Hao Liu; Jun Wan; Mark R Kelley; Mateusz Opyrchal; Nehal J Lakhani; Randall Wireman; Richard A Messmann; Safi Shahda; Sheng Liu

Apr 16, 2025